1. Home
  2. NVO vs MS Comparison

NVO vs MS Comparison

Compare NVO & MS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVO
  • MS
  • Stock Information
  • Founded
  • NVO 1923
  • MS 1924
  • Country
  • NVO Denmark
  • MS United States
  • Employees
  • NVO N/A
  • MS N/A
  • Industry
  • NVO Biotechnology: Biological Products (No Diagnostic Substances)
  • MS Investment Bankers/Brokers/Service
  • Sector
  • NVO Health Care
  • MS Finance
  • Exchange
  • NVO Nasdaq
  • MS Nasdaq
  • Market Cap
  • NVO 278.0B
  • MS 240.2B
  • IPO Year
  • NVO N/A
  • MS N/A
  • Fundamental
  • Price
  • NVO $54.92
  • MS $156.39
  • Analyst Decision
  • NVO Buy
  • MS Buy
  • Analyst Count
  • NVO 7
  • MS 13
  • Target Price
  • NVO $98.00
  • MS $138.25
  • AVG Volume (30 Days)
  • NVO 14.9M
  • MS 4.6M
  • Earning Date
  • NVO 11-05-2025
  • MS 10-15-2025
  • Dividend Yield
  • NVO 2.24%
  • MS 2.56%
  • EPS Growth
  • NVO 24.25
  • MS 45.57
  • EPS
  • NVO 3.93
  • MS 8.83
  • Revenue
  • NVO $49,108,936,497.00
  • MS $65,612,000,000.00
  • Revenue This Year
  • NVO $10.01
  • MS $12.62
  • Revenue Next Year
  • NVO $9.93
  • MS $4.55
  • P/E Ratio
  • NVO $13.90
  • MS $17.72
  • Revenue Growth
  • NVO 20.91
  • MS 16.92
  • 52 Week Low
  • NVO $45.05
  • MS $94.33
  • 52 Week High
  • NVO $138.22
  • MS $157.77
  • Technical
  • Relative Strength Index (RSI)
  • NVO 46.80
  • MS 71.67
  • Support Level
  • NVO $53.55
  • MS $146.29
  • Resistance Level
  • NVO $55.24
  • MS $157.76
  • Average True Range (ATR)
  • NVO 1.17
  • MS 2.63
  • MACD
  • NVO 0.19
  • MS 0.61
  • Stochastic Oscillator
  • NVO 39.06
  • MS 88.66

About NVO Novo Nordisk A/S

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About MS Morgan Stanley

Morgan Stanley is a massive global financial services firm, with offices in 42 countries and more than 80,000 employees as of year-end 2024. The firm cut its teeth in investment banking and institutional trading, where it maintains a strong presence today, but generates the lion share of its income from wealth and asset management franchises, where it boasted $7.9 trillion in client assets at the end of its most recent fiscal year. After reincorporation as a bank holding company in the wake of the great financial crisis, Morgan Stanley also boasts a top 10 banking franchise by deposits, with nearly $400 billion in customer deposits, predominately attributable to cash sweeps from its wealth management and brokerage businesses.

Share on Social Networks: